Pfizer Inc. (NYSE:PFE) Shares Bought by Matrix Asset Advisors Inc. NY

Matrix Asset Advisors Inc. NY lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 318,813 shares of the biopharmaceutical company's stock after purchasing an additional 65,535 shares during the period. Matrix Asset Advisors Inc. NY's holdings in Pfizer were worth $8,079,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PFE. Tallon Kerry Patrick acquired a new stake in Pfizer during the 4th quarter worth $509,000. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. Venturi Wealth Management LLC raised its stake in Pfizer by 23.1% during the 4th quarter. Venturi Wealth Management LLC now owns 6,181 shares of the biopharmaceutical company's stock worth $164,000 after acquiring an additional 1,159 shares in the last quarter. Finally, Waterfront Wealth Inc. raised its stake in Pfizer by 6.0% during the 4th quarter. Waterfront Wealth Inc. now owns 13,422 shares of the biopharmaceutical company's stock worth $356,000 after acquiring an additional 759 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.09 on Friday, reaching $23.97. 62,625,564 shares of the stock were exchanged, compared to its average volume of 41,335,339. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The business has a fifty day moving average price of $23.26 and a two-hundred day moving average price of $24.89. The firm has a market capitalization of $136.27 billion, a PE ratio of 17.37, a PEG ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the business posted $0.82 earnings per share. The business's revenue was down 7.8% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.18%. Pfizer's payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on PFE shares. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group upped their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.